NEWS 
& MEDIA

MEDIA
CONTACT

Welcome to the Takeda Oncology Newsroom. This section is dedicated to providing the most up-to-date information about our company, our people and our science.

If you are a reporter, please contact:
Phone: 617-444-1400
Email: TakedaOncologyNews@takeda.com

For other Takeda news releases, please visit the Takeda.com Newsroom. 

GO TO TAKEDA NEWSROOM

NEWS
RELEASES

5/22/2020

U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer

READ MORE  
5/14/2020

Takeda to Present Data at Upcoming Virtual Scientific Congresses, Underscoring Breadth of Oncology Portfolio and Emerging Pipeline

READ MORE  
5/14/2020

Takeda China announces ADCETRIS® (brentuximab vedotin) is approved for the treatment of adult patients with CD30-positive Lymphomas

READ MORE